EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs

Por James, Roshan, Vishwakarma, Siddharth, Chivukula, Indira V, Basavaraj, Chetana, Melarkode, Ramakrishnan, Montero, Enrique, Nair, Pradip
Publicado em 2012

Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases

Por Alonso-Ramirez, Ruby, Loisel, Séverine, Buors, Caroline, Pers, Jacques-Olivier, Montero, Enrique, Youinou, Pierre, Renaudineau, Yves
Publicado em 2010

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCL...

Por Rodriguez, Pedro C, Neninger, Elia, García, Beatriz, Popa, Xitlally, Viada, Carmen, Luaces, Patricia, González, Gisela, Lage, Agustin, Montero, Enrique, Crombet, Tania
Publicado em 2011

Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data

Por Vázquez, Ana M., Hernández, Ana M., Macías, Amparo, Montero, Enrique, Gómez, Daniel E., Alonso, Daniel F., Gabri, Mariano R., Gómez, Roberto E.
Publicado em 2012

A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis

Por Rodriguez, Pedro C., Torres-Moya, Roberto, Reyes, Gil, Molinero, Claudino, Prada, Dinorah, Lopez, Ana M., Hernandez, Isabel M., Hernandez, Maria V., Martinez, Jose P., Hernandez, Xochel, Casaco, Angel, Ramos, Mayra, Avila, Yisel, Barrese, Yinet, Montero, Enrique, Hernandez, Patricia
Publicado em 2012